source
- Akeso's ivonescimab shows survival advantage over Keytruda in Chinese lung cancer trialA new data cut from a study comparing ivonescimab, a bispecific antibody from China-based Akeso, with Merck's Keytruda in patients with non-small cell lung cancer was released. The interim results…
- Invivyd appoints chairman Marc Elia as CEO ahead of COVID antibody readoutInvivyd, an infectious-disease biotech, announced that its chairman Marc Elia will also serve as chief executive officer. Elia, who joined the board in 2022 and helped shape the company's scientif…